Thomas Jefferson University

William Kelly

TitleProfessor & Chair JMC
InstitutionThomas Jefferson University
DepartmentChair SKMC
Address834 Chestnut Street
Philadelphia PA 19107
Phone215-955-8874
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R21CA096228     (KELLY, WILLIAM K)Mar 1, 2002 - Feb 28, 2005
    NIH
    Development of Oral Suberoylanilide Hydroxamic Acid
    Role: Principal Investigator
    R01CA217329     (MCNAIR, CHRISTOPHER MICHAEL)Aug 1, 2017 - Jul 31, 2022
    NIH
    Targeting Cell Cycle Alterations to Improve Treatment for Advanced Prostate Cancer
    Role: Co-Principal Investigator
    R01CA255792     (YANG, HUSHAN)Jul 8, 2021 - Jun 30, 2026
    NIH
    Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bao A, Patel S, Mecoli CA, Kelly W, Albayda J, Adler B, Paik J, Christopher-Stine L, Tiniakou E, Kang J. Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis. JAMA Dermatol. 2025 Feb 26. PMID: 40009393.
      Citations:    
    2. Wilson NA, Ruffolo L, Juviler P, Fabiano T, Kelly W, Lillvis D, Edwards M, Vu N, Chiou R, Wallenstein K, Craven A, Klein-Cloud R, Bullaro F, Philipose J, Salik I, Fisher J, Wakeman DS. Neighborhood deprivation is a risk factor for severe child physical abuse: A multicenter cohort investigation. J Trauma Acute Care Surg. 2025 Sep 01; 99(3):453-459. PMID: 39910714.
      Citations:    
    3. Sina EM, Rowe M, Mancuso G, Garber G, Kelly WK, Leader AE. Evaluating the Impact of a Novel Program to Address Acute Food Insecurity Among Cancer Patients. Nutrients. 2024 Dec 23; 16(24). PMID: 39771029.
      Citations:    
    4. Marshall CH, Teply BA, Lu J, Oliveira L, Wang H, Mao SS, Kelly WK, Paller CJ, Markowski MC, Denmeade SR, King S, Sullivan R, Davicioni E, Proudfoot JA, Eisenberger MA, Carducci MA, Lotan TL, Antonarakis ES. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Oct 01; 10(10):1400-1408. PMID: 39172479.
      Citations:    
    5. Paller CJ, Zahurak ML, Mandl A, Metri NA, Lalji A, Heath E, Kelly WK, Hoimes C, Barata P, Taksey J, Garrison DA, Patra K, Milne GL, Anders NM, Nauroth JM, Durham JN, Marshall CH, Markowski MC, Eisenberger MA, Antonarakis ES, Carducci MA, Denmeade SR, Levine M. High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. Cancer Res Commun. 2024 08 01; 4(8):2174-2182. PMID: 39076107.
      Citations:    
    6. Verrillo CE, Quaglia F, Shields CD, Lin S, Kossenkov AV, Tang HY, Speicher D, Naranjo NM, Testa A, Kelly WK, Liu Q, Leiby B, Musante L, Sossey-Alaoui K, Dogra N, Chen TY, Altieri DC, Languino LR. Expression of the aV?3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2. J Extracell Vesicles. 2024 Aug; 13(8):e12482. PMID: 39105261.
      Citations:    
    7. Quintanilha JCF, Kelly WK, Innocenti F. Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. Pharmacogenomics J. 2024 Jul 12; 24(4):22. PMID: 38992025.
      Citations:    
    8. Naranjo NM, Kennedy A, Testa A, Verrillo CE, Altieri AD, Kean R, Hooper DC, Yu J, Zhao J, Abinader O, Pickles MW, Hawkins A, Kelly WK, Mitra R, Languino LR. Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma. Cancer Biol Ther. 2024 Dec 31; 25(1):2364433. PMID: 38926911.
      Citations:    
    9. Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-?2 levels in metastatic colorectal cancer patients (Alliance). BMC Genomics. 2024 May 14; 25(1):473. PMID: 38745123.
      Citations:    
    10. Patel JN, Jiang C, Owzar K, Hertz DL, Wang J, Mulkey FA, Kelly WK, Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6. PMID: 38438359.
      Citations:    
    11. Loeb S, Keith SW, Cheng HH, Leader AE, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown LH, Pieczonka CM, Gomella LG, Kelly WK, Lallas CD, Handley N, Mille PJ, Mark JR, Brown GA, Chopra S, McClellan A, Wise DR, Hollifield L, Giri VN. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precis Oncol. 2024 Mar; 8:e2300552. PMID: 38452310.
      Citations:    
    12. Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Xaluritamig, a STEAP1 ? CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024 01 12; 14(1):76-89. PMID: 37861461.
      Citations:    
    13. Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song WM, Fujiwara N, Li P, Mendizabal I, Petrylak DP, Kelly WK, Reddy EP, Wang L, Schiewer MJ, Lujambio A, Karnes J, Knudsen KE, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Cancer Discov. 2023 12 12; 13(12):2584-2609. PMID: 37676710.
      Citations:    
    14. Zhang Z, Luo R, Kelly WK, Chen J, Donahue S, Ip K, Handley NR, Tester WJ, Tsang ML, Kim FJ, Myers R, Lu-Yao G, Gu J, Lin J, Li B, Wang C, Yang H. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27(2):339-347. PMID: 38057610.
      Citations:    
    15. Quintanilha JCF, Sibley AB, Liu Y, Niedzwiecki D, Halabi S, Rogers L, O'Neil B, Kindler H, Kelly W, Venook A, McLeod HL, Ratain MJ, Nixon AB, Innocenti F, Owzar K. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-?2 levels in metastatic colorectal cancer patients (Alliance). medRxiv. 2023 Dec 04. PMID: 38106038.
      Citations:    
    16. Testa A, Quaglia F, Naranjo NM, Verrillo CE, Shields CD, Lin S, Pickles MW, Hamza DF, Von Schalscha T, Cheresh DA, Leiby B, Liu Q, Ding J, Kelly WK, Hooper DC, Corey E, Plow EF, Altieri DC, Languino LR. Targeting the aV?3/NgR2 pathway in neuroendocrine prostate cancer. Matrix Biol. 2023 12; 124:49-62. PMID: 37956856.
      Citations:    
    17. Gomaa S, Kelly WK, Mitchell E, Storozynsky E, Zeigler-Johnson C, Juon HS, Wen KY. Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data. World J Urol. 2023 Sep; 41(9):2351-2357. PMID: 37555986.
      Citations:    
    18. Kelly W, Diaz Duque AE, Michalek J, Konkel B, Caflisch L, Chen Y, Pathuri SC, Madhusudanannair-Kunnuparampil V, Floyd J, Brenner A. Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma. Clin Cancer Res. 2023 07 05; 29(13):2419-2425. PMID: 37093199.
      Citations:    
    19. Zarrabi KK, Narayan V, Mille PJ, Zibelman MR, Miron B, Bashir B, Kelly WK. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol. 2023 Jan-Dec; 15:17562872231182219. PMID: 37359737.
      Citations:    
    20. Mark JR, Gomella LG, Lallas CD, Smentkowski KE, Calvaresi A, Handley N, Den RB, Mille P, Tester WJ, Hoffman-Censits J, Dicker AP, Klonicke E, Halpern E, McCue P, Kelly WK, Trabulsi EJ. Enhancing bladder cancer care through the multidisciplinary clinic approach. Can J Urol. 2023 06; 30(3):11526-11531. PMID: 37344462.
      Citations:    
    21. Mecoli CA, Chee B, Chen M, Wang X, Albayda J, Paik JJ, Tiniakou E, Adler B, Kelly W, Mammen AL, Platz EA, Casciola-Rosen L, Christopher-Stine L, Shah AA. Diagnostic Yield of Computed Tomography for Cancer Detection in a Tertiary Referral Population of Idiopathic Inflammatory Myositis Patients. Arthritis Care Res (Hoboken). 2023 10; 75(10):2142-2150. PMID: 36913182.
      Citations:    
    22. Fradin J, Kim FJ, Lu-Yao GL, Storozynsky E, Kelly WK. Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer. Cancers (Basel). 2023 Apr 15; 15(8). PMID: 37190244.
      Citations:    
    23. Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Na?ve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 05 20; 41(15):2736-2746. PMID: 37040594.
      Citations:    
    24. Chung MP, Lovell J, Kelly W, Mecoli CA, Albayda J, Christopher-Stine L, Gilotra NA, Paik JJ. Myocarditis in Patients With Idiopathic Inflammatory Myopathies: Clinical Presentation and Outcomes. J Rheumatol. 2023 08; 50(8):1039-1046. PMID: 37003604.
      Citations:    
    25. Sim?o DC, Zarrabi KK, Mendes JL, Luz R, Garcia JA, Kelly WK, Barata PC. Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers (Basel). 2023 Feb 23; 15(5). PMID: 36900202.
      Citations:    
    26. Tiniakou E, Mecoli CA, Kelly W, Albayda J, Paik JJ, Adler BL, Lin CT, Mammen AL, Danoff SK, Casciola-Rosen L, Christopher-Stine L. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population. Clin Exp Rheumatol. 2023 03; 41(2):309-315. PMID: 36826791.
      Citations:    
    27. Dhital B, Santasusagna S, Kirthika P, Xu M, Li P, Carceles-Cordon M, Soni RK, Li Z, Hendrickson RC, Schiewer MJ, Kelly WK, Sternberg CN, Luo J, Lujambio A, Cordon-Cardo C, Alvarez-Fernandez M, Malumbres M, Huang H, Ertel A, Domingo-Domenech J, Rodriguez-Bravo V. Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer. Cell Rep Med. 2023 02 21; 4(2):100937. PMID: 36787737.
      Citations:    
    28. Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yamoah K. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. J Natl Cancer Inst. 2022 12 08; 114(12):1656-1664. PMID: 36053178.
      Citations:    
    29. Foss H, Ragam R, Kelly WK, Gomella LG. Neuroendocrine transformation of prostate adenocarcinoma with corpora cavernosa metastases. Can J Urol. 2022 12; 29(6):11399-11401. PMID: 36495584.
      Citations:    
    30. Tripathy S, Alvarez N, Jaiswal S, Williams R, Al-Khadimi M, Hackman S, Phillips W, Kaur S, Cervantez S, Kelly W, Taverna J. Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report. J Med Case Rep. 2022 Nov 25; 16(1):445. PMID: 36434709.
      Citations:    
    31. Quaglia F, Krishn SR, Sossey-Alaoui K, Rana PS, Pluskota E, Park PH, Shields CD, Lin S, McCue P, Kossenkov AV, Wang Y, Goodrich DW, Ku SY, Beltran H, Kelly WK, Corey E, Klose M, Bandtlow C, Liu Q, Altieri DC, Plow EF, Languino LR. The NOGO receptor NgR2, a novel aV?3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Sci Rep. 2022 11 07; 12(1):18879. PMID: 36344556.
      Citations:    
    32. Elliott ZT, Goldberg Z, Philips R, Johnson JM, Kasner MT, Kelly WK, Osipowicz S, Dampman R, Curry JM. Accrual-Monitoring Practices for Various Disease Trials among AACI Member Cancer Centers. Clin Pract. 2022 Aug 31; 12(5):692-700. PMID: 36136866.
      Citations:    
    33. Shah YB, Shaver AL, Kelly WK, Lu-Yao G. A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. PLoS One. 2022; 17(8):e0273826. PMID: 36037225.
      Citations:    
    34. Xu M, Evans L, Bizzaro CL, Quaglia F, Verrillo CE, Li L, Stieglmaier J, Schiewer MJ, Languino LR, Kelly WK. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Cancers (Basel). 2022 Aug 20; 14(16). PMID: 36011027.
      Citations:    
    35. Shah YB, Shaver AL, Beiriger J, Mehta S, Nikita N, Kelly WK, Freedland SJ, Lu-Yao G. Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review. Cancers (Basel). 2022 Aug 03; 14(15). PMID: 35954437.
      Citations:    
    36. Gomella PT, Mark JR, Giri VN, Kelly WK, Gomella LG. Guidelines on Germline Testing for Urologic Tumor Syndromes. Eur Urol Focus. 2022 05; 8(3):670-673. PMID: 35803854.
      Citations:    
    37. Loeb S, Cheng HH, Leader A, Gross L, Nolasco TS, Byrne N, Wise DR, Hollifield L, Brown LH, Slater E, Pieczonka C, Gomella LG, Kelly WK, Trabulsi EJ, Handley N, Lallas CD, Chandrasekar T, Mille P, Mann M, Mark JR, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri VN. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemp Clin Trials. 2022 08; 119:106821. PMID: 35710085.
      Citations:    
    38. Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022 07; 23(7):899-909. PMID: 35690072.
      Citations:    
    39. Dylgjeri E, Kothari V, Shafi AA, Semenova G, Gallagher PT, Guan YF, Pang A, Goodwin JF, Irani S, McCann JJ, Mandigo AC, Chand S, McNair CM, Vasilevskaya I, Schiewer MJ, Lallas CD, McCue PA, Gomella LG, Seifert EL, Carroll JS, Butler LM, Holst J, Kelly WK, Knudsen KE. A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 01; 28(7):1446-1459. PMID: 35078861.
      Citations:    
    40. Sch?der H, Hope TA, Knopp M, Kelly WK, Michalski JM, Lerner SP, Tawab-Amiri A, Mann BS, Lin DW, Yu EY, Chen RC, Beach GC, Reeves SA, Shankar LK. Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. J Clin Oncol. 2022 05 01; 40(13):1500-1505. PMID: 35015566.
      Citations:    
    41. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan; 126(1):162. PMID: 34853435.
      Citations:    
    42. Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S. Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clin Genitourin Cancer. 2022 04; 20(2):e104-e113. PMID: 35012874.
      Citations:    
    43. Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 02; 126(2):265-274. PMID: 34616010.
      Citations:    
    44. Pal SK, McGregor B, Su?rez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021 11 20; 39(33):3725-3736. PMID: 34491815.
      Citations:    
    45. Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate D, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precis Oncol. 2021; 5. PMID: 34589662.
      Citations:    
    46. Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE. Relevance of pRB Loss in Human Malignancies. Clin Cancer Res. 2022 01 15; 28(2):255-264. PMID: 34407969.
      Citations:    
    47. Chandrasekar T, Kelly WK, Gomella LG. Overview of Prostate Cancer Genetic Testing. Urol Clin North Am. 2021 08; 48(3):279-282. PMID: 34210484.
      Citations:    
    48. Chong W, Zhang Z, Luo R, Gu J, Lin J, Wei Q, Li B, Myers R, Lu-Yao G, Kelly WK, Wang C, Yang H. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. BMC Cancer. 2021 Jun 02; 21(1):655. PMID: 34078304.
      Citations:    
    49. Quintanilha JCF, Liu Y, Etheridge AS, Yazdani A, Kindler HL, Kelly WK, Nixon AB, Innocenti F. Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). Angiogenesis. 2022 02; 25(1):47-55. PMID: 34028627.
      Citations:    
    50. Thakur ML, Tripathi SK, Gomella LG, Salmanoglu E, Kim S, Kelly WK, Keith SW, Intenzo C, McCue P, Hoffman-Censits J, Trabulsi EJ. Imaging urothelial bladder cancer: A VPAC PET targeted approach. Can J Urol. 2021 04; 28(2):10596-10602. PMID: 33872557.
      Citations:    
    51. Quaglia F, Krishn SR, Wang Y, Goodrich DW, McCue P, Kossenkov AV, Mandigo AC, Knudsen KE, Weinreb PH, Corey E, Kelly WK, Languino LR. Differential expression of aV?3 and aV?6 integrins in prostate cancer progression. PLoS One. 2021; 16(1):e0244985. PMID: 33481853.
      Citations:    
    52. Wang C, Zhang Z, Chong W, Luo R, Myers RE, Gu J, Lin J, Wei Q, Li B, Rebbeck TR, Lu-Yao G, Kelly WK, Yang H. Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 Jan 13; 13(2). PMID: 33450815.
      Citations:    
    53. Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG. Preserving Well-being in Patients With Advanced and Late Prostate Cancer. Urology. 2021 09; 155:199-209. PMID: 33373704.
      Citations:    
    54. Penas-Prado M, Theeler BJ, Cordeiro B, Dunkel IJ, Hau P, Mahajan A, Robinson GW, Willmarth N, Aboud O, Aldape K, Butman JA, Gajjar A, Kelly W, Rao G, Raygada M, Siegel C, Romo CG, Armstrong TS, Gilbert MR. Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa097. PMID: 33005896.
      Citations:    
    55. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811. PMID: 32516092.
      Citations:    
    56. Quaglia F, Krishn SR, Daaboul GG, Sarker S, Pippa R, Domingo-Domenech J, Kumar G, Fortina P, McCue P, Kelly WK, Beltran H, Liu Q, Languino LR. Small extracellular vesicles modulated by aV?3 integrin induce neuroendocrine differentiation in recipient cancer cells. J Extracell Vesicles. 2020 May 24; 9(1):1761072. PMID: 32922691.
      Citations:    
    57. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Ann Oncol. 2020 07; 31(7):930-941. PMID: 32289380.
      Citations:    
    58. Woo J, Santasusagna S, Banks J, Pastor-Lopez S, Yadav K, Carceles-Cordon M, Dominguez-Andres A, Den RB, Languino LR, Pippa R, Lallas CD, Lu-Yao G, Kelly WK, Knudsen KE, Rodriguez-Bravo V, Tewari AK, Prats JM, Leiby BE, Gomella LG, Domingo-Domenech J. Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer. J Urol. 2020 10; 204(4):691-700. PMID: 32250729.
      Citations:    
    59. Carceles-Cordon M, Kelly WK, Gomella L, Knudsen KE, Rodriguez-Bravo V, Domingo-Domenech J. Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nat Rev Urol. 2020 05; 17(5):292-307. PMID: 32203305.
      Citations:    
    60. Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, Garcia JA, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM. CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Mol Ther. 2020 05 06; 28(5):1238-1250. PMID: 32208168.
      Citations:    
    61. Hoffman-Censits J, Choi W, Pal S, Trabulsi E, Kelly WK, Hahn NM, McConkey D, Comperat E, Matoso A, Cussenot O, Cancel-Tassin G, Fong MHY, Ross J, Madison R, Ali S. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. Eur Urol Oncol. 2021 04; 4(2):297-300. PMID: 32061548.
      Citations:    
    62. Tan XL, E JY, Lin Y, Rebbeck TR, Lu SE, Shang M, Kelly WK, D'Amico A, Stein MN, Zhang L, Jang TL, Kim IY, Demissie K, Ferrari A, Lu-Yao G. Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancer. Cancer Med. 2020 04; 9(7):2379-2389. PMID: 32035002.
      Citations:    
    63. Lin J, Den RB, Greenspan J, Showalter TN, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Gomella LG, Hurwitz MD, Leiby B, Dicker AP, Kelly WK. Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 04 01; 106(5):939-947. PMID: 32029346.
      Citations:    
    64. Lin J, Song AJ, Hoffman-Censits J, Leiby BE, Tuluc M, Shaw C, Harshyne L, Kean R, Bar-Ad V, Den RB, Hurwitz MD, Louie J, Philipose S, Deshmukh SP, Johnson JM, Dicker AP, Hooper DC, Kelly WK, Lu B. A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer. Am J Clin Oncol. 2020 02; 43(2):82-86. PMID: 31693508.
      Citations:    
    65. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003. PMID: 32368717.
      Citations:    
    66. Lin DW, Shih MC, Aronson W, Basler J, Beer TM, Brophy M, Cooperberg M, Garzotto M, Kelly WK, Lee K, McGuire V, Wang Y, Lu Y, Markle V, Nseyo U, Ringer R, Savage SJ, Sinnott P, Uchio E, Yang CC, Montgomery RB. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. Eur Urol. 2020 05; 77(5):563-572. PMID: 31924316.
      Citations:    
    67. Marascio J, Spratt DE, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, Godwin JL, McCue P, Hurwitz MD, Kelly WK, Lallas CD, Knudsen KE, Gomella LG, Dicker AP, Den RB. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer Prostatic Dis. 2020 06; 23(2):295-302. PMID: 31719663.
      Citations:    
    68. Ryan CJ, Dutta S, Kelly WK, Middleberg R, Russell C, Morris MJ, Taplin ME, Halabi S. Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. Clin Genitourin Cancer. 2020 06; 18(3):222-229.e2. PMID: 32273234.
      Citations:    
    69. Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, Rebbeck TR, Chapman A, Kantoff PW, Cullen J, Gomella L, Kelly WK. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol. 2020 02; 77(2):158-166. PMID: 31420248.
      Citations:    
    70. Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2020 03; 23(1):66-73. PMID: 31053766.
      Citations:    
    71. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 02 10; 37(5):403-410. PMID: 30576268.
      Citations:    
    72. Kelly WK, Knudsen KE. Counterpoint-Prostate Cancer Genomic Analysis: Routine or Research Only? Oncology (Williston Park). 2018 12 17; 32(12):607, 630-2. PMID: 30632133.
      Citations:    
    73. Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate. 2019 03; 79(4):333-339. PMID: 30450585.
      Citations:    
    74. Rodriguez-Bravo V, Pippa R, Song WM, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, Woo J, Koh AP, Ertel A, Lokareddy RK, Cuesta-Dominguez A, Kim RS, Rodriguez-Fernandez I, Li P, Gordon R, Hirschfield H, Prats JM, Reddy EP, Fatatis A, Petrylak DP, Gomella L, Kelly WK, Lowe SW, Knudsen KE, Galsky MD, Cingolani G, Lujambio A, Hoshida Y, Domingo-Domenech J. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. Cell. 2018 08 23; 174(5):1200-1215.e20. PMID: 30100187.
      Citations:    
    75. Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, Fedele C, Kurtoglu S, Tripathi SK, Wang K, Hawkins A, Sayeed A, Goswami CP, Thakur ML, Iozzo RV, Peiper SC, Kelly WK, Languino LR. Prostate cancer sheds the av?3 integrin in vivo through exosomes. Matrix Biol. 2019 04; 77:41-57. PMID: 30098419.
      Citations:    
    76. Hurwitz ME, Markowski P, Yao X, Deshpande H, Patel J, Mortazavi A, Donadio A, Stein MN, Kelly WK, Petrylak DP, Mehnert JM. Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma. Clin Genitourin Cancer. 2018 12; 16(6):437-444.e6. PMID: 30177237.
      Citations:    
    77. Anari F, O'Neill J, Choi W, Chen DYT, Haseebuddin M, Kutikov A, Dulaimi E, Alpaugh RK, Devarajan K, Greenberg RE, Bilusic M, Wong YN, Viterbo R, Hoffman-Censits JH, Lallas CD, Trabulsi EJ, Smaldone M, Geynisman DM, Zibelman M, Lin J, Kelly WK, Uzzo R, McConkey D, Plimack ER. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018 May; 1(1):54-60. PMID: 30420974.
      Citations:    
    78. Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744. PMID: 29871907.
      Citations:    
    79. Mark JR, Kelly WK, Gomella LG. Multidisciplinary Clinical Treatment of Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2018 05 01; 144(5):460-461. PMID: 29543958.
      Citations:    
    80. Lu H, Bowler N, Harshyne LA, Craig Hooper D, Krishn SR, Kurtoglu S, Fedele C, Liu Q, Tang HY, Kossenkov AV, Kelly WK, Wang K, Kean RB, Weinreb PH, Yu L, Dutta A, Fortina P, Ertel A, Stanczak M, Forsberg F, Gabrilovich DI, Speicher DW, Altieri DC, Languino LR. Exosomal av?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol. 2018 09; 70:20-35. PMID: 29530483.
      Citations:    
    81. Grasso I, Haigney M, Mortara D, Collen JF, Hostler J, Moores A, Sheikh K, Kelly W. Detection of sleep-disordered breathing with ambulatory Holter monitoring. Sleep Breath. 2018 Dec; 22(4):1021-1028. PMID: 29353391.
      Citations:    
    82. Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 2018 01 01; 29(1):23-25. PMID: 29088323.
      Citations:    
    83. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424. PMID: 29236593.
      Citations:    
    84. Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol. 2017 Aug; 40(4):342-347. PMID: 25723740.
      Citations:    
    85. Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol. 2017 Aug 01; 3(8):1043-1050. PMID: 28208174.
      Citations:    
    86. Giri VN, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty SE, Montgomery S, Forman A, Bingler R, Kelly WK, Dicker AP, Winheld S, Trabulsi EJ, Chen DYT, Lallas CD, Allen BA, Daly MB, Gomella LG. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precis Oncol. 2017 May; 1. PMID: 34164591.
      Citations:    
    87. Truong H, Hegarty SE, Gomella LG, Kelly WK, Trabulsi EJ, Lallas CD, Giri VN. Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts. J Genet Couns. 2017 Jun; 26(3):548-555. PMID: 28101821.
      Citations:    
    88. Lin J, Patel SA, Sama AR, Hoffman-Censits JH, Kennedy B, Kilpatrick D, Ye Z, Yang H, Mu Z, Leiby B, Lewis N, Cristofanilli M, Kelly WK. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. Oncologist. 2016 11; 21(11):1296-1297e. PMID: 28178640.
      Citations:    
    89. Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, Thangavel C, Seiler R, Feng FY, Schaeffer EM, Trabulsi EJ, Gomella LG, Hurwitz MD, Dicker AP, Den RB. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urol Case Rep. 2016 Nov; 9:51-54. PMID: 27713863.
      Citations:    
    90. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900. PMID: 27143689.
      Citations:    
    91. Li J, Kluger H, Devine L, Lee JJ, Kelly WK, Rink L, Saif MW. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. Cancer Chemother Pharmacol. 2016 06; 77(6):1193-200. PMID: 27103123.
      Citations:    
    92. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9. PMID: 26951312.
      Citations:    
    93. Geethakumari PR, Cookson MS, Kelly WK. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Oncology (Williston Park). 2016 Feb; 30(2):187-95, 199. PMID: 26888794.
      Citations:    
    94. Selvan SR, Dowling JP, Kelly WK, Lin J. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. Curr Cancer Drug Targets. 2016; 16(9):755-764. PMID: 26517538.
      Citations:    
    95. Silberstein JL, Poon SA, Sjoberg DD, Maschino AC, Vickers AJ, Bernie A, Konety BR, Kelly WK, Eastham JA. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer. BJU Int. 2015 Jul; 116(1):50-6. PMID: 24552276.
      Citations:    
    96. de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, Kelly WK, Trabulsi EJ, Lallas CD, Gomella LG, Knudsen KE. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015 Feb 15; 21(4):795-807. PMID: 25691773.
      Citations:    
    97. Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31. PMID: 25417775.
      Citations:    
    98. Den RB, Kelly WK. Effect of docetaxel on safety and efficacy of radium-223. Lancet Oncol. 2014 Nov; 15(12):1292-3. PMID: 25439686.
      Citations:    
    99. Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1038-1046. PMID: 25035207.
      Citations:    
    100. Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20; 32(18):1895-901. PMID: 24821881.
      Citations:    
    101. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50. PMID: 24590644.
      Citations:    
    102. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Mar 01; 32(7):671-7. PMID: 24449231.
      Citations:    
    103. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43. PMID: 23913744.
      Citations:    
    104. Jacobs DI, Mao Y, Fu A, Kelly WK, Zhu Y. Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray. BMC Urol. 2013 Jul 26; 13:37. PMID: 23890537.
      Citations:    
    105. Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine. 2013 Nov; 9(8):1124-34. PMID: 23764660.
      Citations:    
    106. Lin J, Yang H, Kelly WK. Prostate cancer biomarker: a key field to explore. Asian J Androl. 2013 May; 15(3):358-9. PMID: 23435472.
      Citations:    
    107. Lin J, Kelly WK. Targeting angiogenesis as a promising modality for the treatment of prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):547-60. PMID: 23084530.
      Citations:    
    108. Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013 Feb; 24(2):343-349. PMID: 23022995.
      Citations:    
    109. Fayez R, Roy M, Villeneuve S, AlMuntashery A, Demyttenaere S, Christou N, Court O, AlMuntashery A, Fayez R, Demyttenaere S, Christou N, Court O, Bodie G, Bonrath E, Hagen J, Okrainec A, Sullivan P, Grantcharov T, Almamar A, Sharma A, Karmali S, Birch DW, Gill RS, Majumdar SR, Wang X, Tuepah R, Klarenbach SW, Birch DW, Karmali S, Sharma AM, Padwal RJ, Ra?che I, Smith C, Haggar F, Moloo H, Poulin EC, Martel G, Yelle JD, Mamazza J, Mueller CL, Jackson TD, Penner T, Pitzul K, Urbach DR, Okrainec A, AlMuntashery A, Villeneuve S, Roy M, Fayez R, Demyttenaere S, Christou N, Court O, Fayez R, Roy M, Villeneuve S, AlMuntashery A, Demyttenaere S, Christou N, Court O, AlMuntashery A, Fayez R, Demyttenaere S, Court O, Christou N, Moustarah F, Biertho L, Hould FS, Lebel S, Lescelleur O, Marceau S, Marceau P, Biron S, Khokhotva M, Grantcharov T, Anvari M, Sharma A, Yusuf S, Kwong J, Okrainec A, Pitzul KB, Urbach DR, Jackson T, Elkassem S, Lindsay D, Sullivan P, Smith L, Bonrath E, Zevin B, Dedy N, Grantcharov TP, Zevin B, Bonrath EM, Aggarwal R, Grantcharov T, Sockalingam S, Cassin S, Crawford S, Pitzul K, Khan A, Hawa R, Jackson T, Okrainec A, Smith C, Brar B, Mamazza J, Ra?che I, Yelle JD, Haggar F, Moloo H, Smith C, Brar B, Haggar F, Dent R, Mamazza J, Ra?che I, Moloo H, Whitlock KA, Gill RS, Ali T, Shi X, Birch DW, Karmali S, Gill RS, Whitlock KA, Shi X, Sarkhosh K, Birch DW, Karmali S, Suri M, Turner JM, Nation PN, Wizzard P, Brubaker PL, Gisalet DL, Wales PW, Palter VN, Grantcharov TP, Wakeam E, Tien H, Spencer F, Brenneman F, Khan RSA, Kowal J, Wiseman SM, Martelli V, Fraser SA, Vedel I, Deban M, Holcroft C, Monette M, Monette J, Bergman S, Malik A, Bell C, Stukel T, Urbach DR, Young PY, Mueller TF, Lucykx VA, Lukowski CM, Compston CA, Churchill TA, Khadaroo RG, Daigle C, Grantcharov T, McCreery G, Vogt K, Dubois L, Gray D, Seth R, Ananth A, Tai LH, Lam T, Falls T, Souza C, Bell J, Auer R, Paskar D, Crawford S, Parry N, Leslie K, Sudarshan M, Alhabboubi M, St-Louis E, Deckelbaum D, Razek T, Feldman LS, Khwaja K, Richardson D, Porter G, Johnson P, Haggar F, Boushey R, Moloo H, Raiche I, Mamazza J, Davis VW, Schiller DE, Eurich D, Sawyer MB, Rivard J, Vergis A, Unger B, Hardy K, Andrew C, Gillman L, Park J, Agzarian J, Prodger J, Kelly W, Kelly S, Prodger D, Racz J, Ewara E, Martin J, Sarma S, Chu M, Schlachta C, Zaric G, Winocour J, Al-Ali K, Briggs K, George R, Zilbert NR, Murnaghan ML, Leung A, Regehr G, Moulton CA, Decker C, Neumann K, Mahmud S, Metcalfe J, McKay A, Park J, Hochman D, Gosney JE, Burkle FM, Redmond AD, McQueen K, Wissanji H, Desrosiers E, Gilbert A, Chadi SA, Leslie K, Ott MC, Alhabboubi M, Sudarshan M, Jessula S, Alburakan A, Deckelbaum D, Razek T, Iqbal S, Khwaja K, Partridge E, Aikins C, Alhabboubi M, Sudarshan M, Deckelbaum D, Iqbal S, Khwaja K, Razek T, Olszewski M, Roberts N, Moulton CA, Murnaghan ML, Cil T, Chan R, Marshall J, Pederson K, Erichsen S, White J, Nadler A, Aarts MA, Okrainec A, Victor JC, Pearsall E, McLeod RS, Hameed U, Jackson TD, Okrainec A, Penner TP, Urbach DR, Brotherhood H, Karimuddin A, Hall C, Bawan S, Malik S, Hayashi A, Menezes AS, Gill RS, McAlister C, Zhang N, DesRosiers E, Mills A, Crozier M, Lee L, Maxwell J, Partridge E, Chad S, Steigerwald S, Mapiour D, Roberts D, MacPherson C, Donahoe L, MacDonald B, Mercer D, Hopman W, Rakovich G, Latulippe JF, Hilsden R, Knowles S, Moffat B, Parry N, Leslie K, Merani S, Switzer N, Khadaroo RG, Tul Y, Widder S, Davis P, Molinari M, Levy A, Johnson P, Davis PJB, Bailey J, Molinari M, Hayden J, Johnson P, Cools-Lartigue J, Benlolo S, Marcus V, Ferri L, Ojah J, Finley R, Anderson D, Julien F, Gagn? JP, Carter D, Chan S, Wong S, Li J, Michael A, Choi D, Liu E, Hoogenes J, Dath D, Pitt D, Aubin JM, Banks BA, Mew D, McConnell Y, Rudovics A, Classen D, Kanthan S, Ravichandran P, Croome KP, Kovacs MJ, Lazo-Langner A, Hernandez-Alejandro R, Anantha R, Vogt K, Crawford S, Parry N, Leslie K, Aad I, Kholdebarin R, Khoshgoo N, Iwasiow BM, et al. Canadian Surgery Forum. Can J Surg. 2012 Aug; 55(4 Suppl 1):S63-S135. PMID: 35488395.
      Citations:    
    110. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 01; 30(13):1534-40. PMID: 22454414.
      Citations:    
    111. Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 01; 118(17):4139-47. PMID: 22180287.
      Citations:    
    112. Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA. 2011 Dec 07; 306(21):2382-3. PMID: 22147384.
      Citations:    
    113. Kazer MW, Bailey DE, Sanda M, Colberg J, Kelly WK. An Internet intervention for management of uncertainty during active surveillance for prostate cancer. Oncol Nurs Forum. 2011 Sep; 38(5):561-8. PMID: 21875843.
      Citations:    
    114. Gomella LG, Gelpi F, Kelly WK. New treatment options for castrate-resistant prostate cancer: a urology perspective. Can J Urol. 2011 Aug; 18(4):5767-77. PMID: 21854708.
      Citations:    
    115. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011 Aug; 60(2):279-90. PMID: 21592649.
      Citations:    
    116. Knudsen KE, Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab. 2011 May; 6(3):483-493. PMID: 22389648.
      Citations:    
    117. Kazer MW, Bailey DE, Colberg J, Kelly WK, Carroll P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. J Clin Nurs. 2011 Feb; 20(3-4):581-6. PMID: 21219530.
      Citations:    
    118. Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, Zheng T, Zhu Y. Genome-wide methylation analysis identifies involvement of TNF-a mediated cancer pathways in prostate cancer. Cancer Lett. 2011 Mar 01; 302(1):47-53. PMID: 21237555.
      Citations:    
    119. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 01; 117(3):526-33. PMID: 20862750.
      Citations:    
    120. Hoimes CJ, Kelly WK. Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol. 2010 Mar 01; 2(2):107-123. PMID: 20543967.
      Citations:    
    121. Kelly WK. Epothilones in prostate cancer. Urol Oncol. 2011 Jul-Aug; 29(4):358-65. PMID: 19914096.
      Citations:    
    122. Kelly W, Arellano F, Barnes J, Bergman U, Edwards R, Fernandez A, Freedman S, Goldsmith D, Huang K, Jones J, McLeay R, Moore N, Stather R, Trenque T, Troutman W, van Puijenbroek E, Williams F, Wise R. Guidelines for submitting adverse event reports for publication. Therapie. 2009 Jul-Aug; 64(4):289-94. PMID: 19804709.
      Citations:    
    123. Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher HI. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2009 Oct; 7(3):E77-82. PMID: 19815486.
      Citations:    
    124. Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol. 2010 Feb; 21(2):312-318. PMID: 19633053.
      Citations:    
    125. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009 May 01; 15(9):3172-6. PMID: 19366825.
      Citations:    
    126. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 May 20; 27(15):2436-42. PMID: 19364960.
      Citations:    
    127. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009 Aug; 56(2):237-44. PMID: 19375217.
      Citations:    
    128. Lee JJ, Kelly WK. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol. 2009 Feb; 6(2):85-92. PMID: 19048010.
      Citations:    
    129. Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer. 2008 Dec 01; 113(11):3137-45. PMID: 18989865.
      Citations:    
    130. Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer. 2008 Sep; 6(2):110-6. PMID: 18824434.
      Citations:    
    131. Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM, Camp RL. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest. 2008 Sep; 88(9):962-72. PMID: 18626467.
      Citations:    
    132. Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother. 2008 Jul-Aug; 31(6):569-76. PMID: 18528297.
      Citations:    
    133. Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, Lin DW. Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology. 2008 Sep; 72(3):474-80. PMID: 18407333.
      Citations:    
    134. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008 May 01; 26(13):2147-54. PMID: 18362364.
      Citations:    
    135. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 01; 26(7):1148-59. PMID: 18309951.
      Citations:    
    136. Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J Urol. 2007 Dec; 178(6):2378-83; discussion 2383-4. PMID: 17936848.
      Citations:    
    137. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007 Nov; 8(11):994-1000. PMID: 17942366.
      Citations:    
    138. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 01; 110(3):556-63. PMID: 17577218.
      Citations:    
    139. Kantoff PW, Beer TM, D'Amico AV, Dipaola RS, Eisenberger MA, Hussain MH, Kelly WK, Mathew P, Morris MJ, Ryan CJ, Sandler HM, Thompson IM, Carroll PR. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4. PMID: 17644118.
      Citations:    
    140. Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol Immunother. 2007 Dec; 56(12):1921-30. PMID: 17619878.
      Citations:    
    141. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1775-82. PMID: 17363532.
      Citations:    
    142. Galsky MD, Kelly WK. High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care? Nat Clin Pract Urol. 2007 Mar; 4(3):134-5. PMID: 17297500.
      Citations:    
    143. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006 Jan; 7(4):257-61. PMID: 16512979.
      Citations:    
    144. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 01; 106(1):58-62. PMID: 16329138.
      Citations:    
    145. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006 Jan 01; 24(1):166-73. PMID: 16330674.
      Citations:    
    146. Gleave M, Kelly WK. High-risk localized prostate cancer: a case for early chemotherapy. J Clin Oncol. 2005 Nov 10; 23(32):8186-91. PMID: 16278471.
      Citations:    
    147. Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005 Oct 15; 11(20):7454-61. PMID: 16243819.
      Citations:    
    148. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer. 2005 Sep; 4(2):86-90. PMID: 16197608.
      Citations:    
    149. Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 2005 Jul 15; 11(14):5195-8. PMID: 16033836.
      Citations:    
    150. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res. 2005 Jul 15; 11(14):5223-32. PMID: 16033840.
      Citations:    
    151. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005 Jun 10; 23(17):3923-31. PMID: 15897550.
      Citations:    
    152. Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly WK, Slovin S, Schwartz L, Scher HI. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005 May 01; 11(9):3210-6. PMID: 15867215.
      Citations:    
    153. Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005 Mar; 2(3):150-7. PMID: 16264908.
      Citations:    
    154. Morris MJ, Cordon-Cardo C, Kelly WK, Slovin SF, Siedlecki K, Regan KP, DiPaola RS, Rafi M, Rosen N, Scher HI. Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Appl Immunohistochem Mol Morphol. 2005 Mar; 13(1):6-13. PMID: 15722787.
      Citations:    
    155. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 01; 23(7):1439-46. PMID: 15735119.
      Citations:    
    156. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer. 2005 Jan 01; 103(1):11-21. PMID: 15558815.
      Citations:    
    157. Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer. 2004 Dec; 3(3):174-81. PMID: 15636684.
      Citations:    
    158. Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology. 2004 Jul; 64(1):90-4. PMID: 15245942.
      Citations:    
    159. Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 2004 May 01; 100(9):1868-75. PMID: 15112267.
      Citations:    
    160. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. PMID: 14752077.
      Citations:    
    161. Konety BR, Eastham JA, Reuter VE, Scardino PT, Donat SM, Dalbagni G, Russo P, Herr HW, Schwartz L, Kantoff PW, Scher H, Kelly WK. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol. 2004 Feb; 171(2 Pt 1):709-13. PMID: 14713792.
      Citations:    
    162. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res. 2004; 91:137-68. PMID: 15327890.
      Citations:    
    163. Richon VM, Zhou X, Secrist JP, Cordon-Cardo C, Kelly WK, Drobnjak M, Marks PA. Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. Methods Enzymol. 2004; 376:199-205. PMID: 14975307.
      Citations:    
    164. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003 Dec 29; 62 Suppl 1:55-62. PMID: 14747042.
      Citations:    
    165. Galsky M, Kelly WK. Use of nomograms for predicting survival in patients with castrate prostate cancer. Urology. 2003 Dec 29; 62 Suppl 1:119-27. PMID: 14747049.
      Citations:    
    166. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15; 98(12):2592-8. PMID: 14669278.
      Citations:    
    167. Solit DB, Morris M, Slovin S, Curley T, Schwartz L, Larson S, Kattan MW, Hartley-Asp B, Scher HI, Kelly WK. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003 Nov 01; 98(9):1842-8. PMID: 14584065.
      Citations:    
    168. Kelly WK, Steineck G. Bisphosphonates for men with prostate cancer: sifting through the rubble. J Clin Oncol. 2003 Dec 01; 21(23):4261-2. PMID: 14581442.
      Citations:    
    169. Galsky M, Kelly WK. The development of differentiation agents for the treatment of prostate cancer. Semin Oncol. 2003 Oct; 30(5):689-97. PMID: 14571416.
      Citations:    
    170. Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol. 2003 Oct; 14(10):1518-24. PMID: 14504052.
      Citations:    
    171. Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, Larson S, Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin Cancer Res. 2003 Jun; 9(6):2098-107. PMID: 12796374.
      Citations:    
    172. Verbel DA, Kelly WK, Smaletz O, Regan K, Curley T, Heller G, Scher HI. Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. Urology. 2003 Jan; 61(1):142-4. PMID: 12559285.
      Citations:    
    173. Scher HI, Kelly WK. Editorial: States and state transitions are all that really matter. J Urol. 2002 Dec; 168(6):2451-3. PMID: 12441937.
      Citations:    
    174. Kelly WK, O'Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs. 2002 Dec; 11(12):1695-713. PMID: 12457432.
      Citations:    
    175. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002 Oct 01; 20(19):3972-82. PMID: 12351594.
      Citations:    
    176. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6. PMID: 12231036.
      Citations:    
    177. Kelly WK. Novel trial designs: which agents and how do we test them? Urology. 2002 Sep; 60(3 Suppl 1):109-13; discussion 113-4. PMID: 12231064.
      Citations:    
    178. Verbel DA, Heller G, Kelly WK, Scher HI. Quantifying the amount of variation in survival explained by prostate-specific antigen. Clin Cancer Res. 2002 Aug; 8(8):2576-9. PMID: 12171886.
      Citations:    
    179. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res. 2002 Mar; 8(3):679-83. PMID: 11895895.
      Citations:    
    180. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. HER-2 profiling and targeting in prostate carcinoma. Cancer. 2002 Feb 15; 94(4):980-6. PMID: 11920466.
      Citations:    
    181. Steineck G, Reuter V, Kelly WK, Frank R, Schwartz L, Scher HI. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta Oncol. 2002; 41(7-8):668-74. PMID: 14651212.
      Citations:    
    182. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001 Dec; 1(3):194-202. PMID: 11902574.
      Citations:    
    183. Turlakow A, Larson SM, Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med. 2001 Sep; 45(3):235-44. PMID: 11788816.
      Citations:    
    184. Nielsen K, Gall D, Smith P, Kelly W, Yeo J, Kenny K, Heneghan T, McNamara S, Maher P, O'Connor J, Walsh B, Carroll J, Rojas X, Rojas F, Perez B, Wulff O, Buffoni L, Salustio E, Gregoret R, Samartino L, Dajer A, Luna-Martinez E. Fluorescence polarization assay for the diagnosis of bovine brucellosis: adaptation to field use. Vet Microbiol. 2001 May 21; 80(2):163-70. PMID: 11295336.
      Citations:    
    185. Sherman EJ, Pfister DG, Ruchlin HS, Rubin DM, Radzyner MH, Kelleher GH, Slovin SF, Kelly WK, Scher HI. The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma. Cancer. 2001 Feb 15; 91(4):841-53. PMID: 11241254.
      Citations:    
    186. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001 Jan 01; 19(1):44-53. PMID: 11134194.
      Citations:    
    187. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000 Nov 01; 18(21):3595-603. PMID: 11054432.
      Citations:    
    188. Kelly WK, Slovin SF. Chemotherapy for androgen- independent prostate cancer: myth or reality. Curr Oncol Rep. 2000 Sep; 2(5):394-401. PMID: 11122870.
      Citations:    
    189. Zelefsky MJ, Kelly WK, Scher HI, Lee H, Smart T, Metz E, Schwartz L, Fuks Z, Leibel SA. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol. 2000 May; 18(9):1936-41. PMID: 10784635.
      Citations:    
    190. Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer. 2000 Apr 01; 88(7):1671-8. PMID: 10738226.
      Citations:    
    191. Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus DM, Scher HI. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin Cancer Res. 2000 Mar; 6(3):838-46. PMID: 10741705.
      Citations:    
    192. Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, Icasiano E, Boyle MG, Bajorin DF. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol. 2000 Feb; 18(4):840-6. PMID: 10673526.
      Citations:    
    193. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999 Mar; 17(3):948-57. PMID: 10071289.
      Citations:    
    194. Burmeister BH, Gogna NK, Bryant GP, Armstrong J, Kelly W, Mackintosh J, Walpole E, Morton K. Chemoradiation for inoperable non small cell lung cancer: a phase II study using a regimen with acceptable toxicity. Lung Cancer. 1999 Mar; 23(3):233-40. PMID: 10413199.
      Citations:    
    195. Schwartz LH, LaTrenta LR, Bonaccio E, Kelly WK, Scher HI, Panicek DM. Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. Radiology. 1998 Sep; 208(3):735-8. PMID: 9722854.
      Citations:    
    196. Bajorin DF, McCaffrey JA, Hilton S, Mazumdar M, Kelly WK, Scher HI, Spicer J, Herr H, Higgins G. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol. 1998 Aug; 16(8):2722-7. PMID: 9704723.
      Citations:    
    197. Wolchok JD, Herr HW, Kelly WK. Localized squamous cell carcinoma of the bladder causing hypercalcemia and inhibition of PTH secretion. Urology. 1998 Mar; 51(3):489-91. PMID: 9510360.
      Citations:    
    198. Slovin SF, Kelly WK, Scher HI. Immunological approaches for the treatment of prostate cancer. Semin Urol Oncol. 1998 Feb; 16(1):53-9. PMID: 9508084.
      Citations:    
    199. Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol. 1998; 34 Suppl 3:18-23. PMID: 9854191.
      Citations:    
    200. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 1997 Aug; 15(8):2928-38. PMID: 9256137.
      Citations:    
    201. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol. 1997 Jun; 15(6):2449-55. PMID: 9196161.
      Citations:    
    202. Kelly WK, Slovin S, Scher HI. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am. 1997 May; 24(2):421-31. PMID: 9126240.
      Citations:    
    203. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May; 15(5):1853-7. PMID: 9164195.
      Citations:    
    204. Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn J, Scher HI. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Semin Oncol. 1996 Dec; 23(6 Suppl 14):41-8. PMID: 8996585.
      Citations:    
    205. Kelly WK, Slovin S, Scher HI. Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 14):8-14. PMID: 8996578.
      Citations:    
    206. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst. 1996 Nov 20; 88(22):1623-34. PMID: 8931606.
      Citations:    
    207. Steineck G, Kelly WK, Mazumdar M, Vlamis V, Schwartz M, Scher HI. Acid phosphatase: defining a role in androgen-independent prostate cancer. Urology. 1996 May; 47(5):719-26. PMID: 8650872.
      Citations:    
    208. Scher HI, Zhang ZF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology. 1996 Jan; 47(1A Suppl):61-9. PMID: 8560680.
      Citations:    
    209. Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. J Clin Oncol. 1995 Sep; 13(9):2214-22. PMID: 7666079.
      Citations:    
    210. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol. 1995 Sep; 13(9):2208-13. PMID: 7545218.
      Citations:    
    211. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 1995 Aug; 46(2):142-8. PMID: 7624983.
      Citations:    
    212. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol. 1995 May; 13(5):1195-200. PMID: 7537803.
      Citations:    
    213. Schultz PK, Kelly WK, Begg C, Liebertz C, Cohen L, Scher HI. Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin. Urology. 1994 Aug; 44(2):237-42. PMID: 7519382.
      Citations:    
    214. Kelly WK, Scher HI. Prostate cancer: how can a common disease be so controversial? Curr Opin Oncol. 1994 May; 6(3):318-31. PMID: 8080862.
      Citations:    
    215. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993 Aug; 11(8):1566-72. PMID: 7687666.
      Citations:    
    216. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993 Apr; 11(4):607-15. PMID: 7683043.
      Citations:    
    217. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993 Mar; 149(3):607-9. PMID: 7679759.
      Citations:    
    218. Mautner RK, Katz GE, Kelly W, Phillips JH. Chronic ventricular dysrhythmia in the mitral valve prolapse syndrome: frequency and clinical significance of ventricular site of origin. South Med J. 1980 Sep; 73(9):1229-33. PMID: 7414382.
      Citations:    
    219. Elkort RJ, Kelly W, Mozden PJ, Feldman MI. A combined treatment program for the management of locally recurrent breast cancer following chest wall irradiation. Cancer. 1980 Aug 15; 46(4):647-53. PMID: 6994871.
      Citations:    
    Kelly's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (615)
    Explore
    _
    Co-Authors (84)
    Explore
    _
    Similar People (59)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _